Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response
Journal of Virology · 22.07.2025 · 99 (7)
DOI: 10.1128/jvi.00394-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 22.07.2025. Verfasst von Andrea Cottignies-Calamarte und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Mucosal Entry of HIV and Mucosal Immunity Institut Cochin, Paris, France. Hauptthemen laut MEDLINE: Autophagy, SARS-CoV-2, AMP-Activated Protein Kinases, Interferon Type I. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation pour la Recherche Médicale.
Abstract (Originalsprache)
AMP-activated protein kinase (AMPK) plays a central role in regulating cell energy balance. When activated, AMPK suppresses energy-consuming pathways, such as lipid and protein synthesis, while increasing nutrient availability through the activation of autophagy. These pathways downstream of AMPK activation contribute to SARS-CoV-2 infection, which hijacks autophagy and accumulates lipid droplets in viral factories to support viral replication. Here, we assessed the antiviral activity of the direct pan-AMPK allosteric activator MK-8722 in vitro . MK-8722 efficiently inhibited infection of Alpha and Omicron SARS-CoV-2 variants in Vero76 and human bronchial epithelial Calu-3 cells at micromolar concentration. This inhibition relied on restoring the autophagic flux, which redirected newly synthesized viral proteins for degradation, and reduced lipid metabolism, which affected viral factories. Furthermore, MK-8722 treatment increased the type I interferon (IFN-I) response. Post-infection treatment with MK-8722 was enough to inhibit efficient viral replication and restore the IFN-I response. Finally, MK-8722 treatment did not alter the SARS-CoV-2-specific CD8 + T cell response mounted upon Spike vaccination. Overall, by activating AMPK, MK-8722 acts as an effective antiviral against SARS-CoV-2 infection, even when applied post-exposure, paving the way for preclinical tests aimed at inhibiting viral replication and improving patients’ symptoms. IMPORTANCE Coronavirus disease 2019, caused by SARS-CoV-2 infection, has led to severe acute respiratory syndrome with very high mortality. Despite available vaccines and public health measures, new SARS-CoV-2 variants emerge with increased transmissibility requiring the development of novel therapeutic strategies. Recently, the AMP-activated protein kinase (AMPK), a cellular energy sensor, has emerged as a potential broad-spectrum antiviral target, as AMPK can modulate the intracellular environment in turn impeding viral replication. This study aims to evaluate the potential of pharmacological activation of AMPK to inhibit SARS-CoV-2 infection and replication. Our findings demonstrate that AMPK activation induces significant alterations in host cellular lipid metabolism that disrupt viral factories essential for SARS-CoV-2 replication. Furthermore, by enhancing autophagy, a process crucial for the degradation and clearance of viral particles, AMPK activation facilitates the elimination of the virus. Therefore, targeting AMPK signaling pathways could offer a promising therapeutic approach for the treatment of SARS-CoV-2 infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Mucosal Entry of HIV and Mucosal Immunity Institut Cochin, Paris, France.
- Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France.
- Virologie moléculaire et cellulaire des coronavirus, Center d'infection et d'immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHRU, Lille, France.
ORCID-Profile: Jean Dubuisson, Morgane Bomsel
Förderung
- Fondation pour la Recherche Médicale
Zitieren
APA
Cottignies-Calamarte, A., Marteau, F., He, F., Belouzard, S., Dubuisson, J., Tudor, D., Viollet, B., & Bomsel, M. (2025). Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response. Journal of Virology, 99(7). https://doi.org/10.1128/jvi.00394-25
Vancouver
Cottignies-Calamarte A, Marteau F, He F, Belouzard S, Dubuisson J, Tudor D, et al. Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response. Journal of Virology. 2025;99(7). doi:10.1128/jvi.00394-25
BibTeX
@article{CottigniesCalamarte2025,
author = {Cottignies-Calamarte, Andrea and Marteau, Flora and He, Feifan and Belouzard, Sandrine and Dubuisson, Jean and Tudor, Daniela and Viollet, Benoit and Bomsel, Morgane},
title = {Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response},
journal = {Journal of Virology},
year = {2025},
volume = {99},
number = {7},
doi = {10.1128/jvi.00394-25}
}
EUVIMED